Vince and Associates Clinical Research, Inc.
Overland Park, Kansas, 66212, United States
NCT Number: NCT02750748
To determine the pharmacokinetics of 2 intranasal doses and 1 oral dose of naltrexone compared to an intramuscular dose of naltrexone.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Overland Park, Kansas, 66212, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 48 hours
Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration
Time frame: 48 hours
Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration
Time frame: 48 hours
Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration
Time frame: 48 hours
Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration
Time frame: Maximum of 18 days
Will be reported from the start of the first session to follow-up visit
Time frame: 12 days
Measured before and after naltrexone administration
Time frame: 12 days
Measured before and after naltrexone administration
Time frame: 5 days
Will be reported from the start of the first session to follow-up visit
National Institute on Drug Abuse (NIDA)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02526212
Chemically-Induced Disorders, Mental Disorders
The Bronx, New York, United States
View Trial DetailsNCT04325659
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT05651516
Brain Diseases, Central Nervous System Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05380440
Amphetamine-Related Disorders, Chemically-Induced Disorders
Eugene, Oregon, United States
View Trial Details